Overview

Efficacy of Opioids and Mexiletine for the Treatment of Postamputation Pain

Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
0
Participant gender:
All
Summary
Persistent pain occurs in 50-85 percent of patients who experience the amputation of an extremity. This study will compare the effectiveness of morphine and mexiletine to placebo in the treatment of postamputation pain. It is hypothesized that the effects of opioids and mexiletine on behavior and mental functioning in patients with postamputation pain are unlikely to be significant barriers to the clinical use of the drugs.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Treatments:
Analgesics, Opioid
Mexiletine
Morphine
Criteria
Inclusion Criteria:

Adults (18 years or older) of both sexes and all races with persistent phantom and or stump
pain for 6 months or longer following an amputation will be eligible for enrollment in the
study.

Exclusion Criteria:

1) age less than 18 or over 85 years, 2) history of allergic reaction to the study drugs,
i.e., morphine and mexiletine, 3) cardiac conduction defects such as second degree or
complete heart block, or a myocardial infarction in the last 3 months, 4) severe pulmonary
disease, 5) current history of alcohol or substance abuse, 6) seizures, dementia or
encephalopathy, 7) pregnancy and nursing mothers, 8) chronic hepatic disease or hepatic
failure, 9) hematological disease associated with leukopenia and/or thrombocytopenia, and
10) other terminal illness with a life expectancy of less than 6 months. 11) Finally, to
avoid a bias in patient selection, patients who failed to achieve clinically significant
pain relief to a previous optimal trial with morphine and/or mexiletine will be excluded.
An optimal trial will be defined as minimum of 3 week trial with either agent using a drug
titration paradigm where the dose of the drugs were increased at intervals of one week or
less.